Publication at Faculty of Medicine in Hradec Králové |
2012
Abstract
Intravitreal injection of ranibizumab, a recombinant humanized monoclonal antibodies blocking VEGF-A (Vascular Endothelial Growth Factor A) is an effective treatment for the wet form of age-related macular degeneration, macular edema in retinal vein occlusion, and diabetic macular edema. A blockade of VEGF leads to interference of the permeability of retinal and choroidal blood vessels, angiogenesis and choroidal vascular proliferation, cytokine production and influences the inflammatory response.
Expanded use of ranibizumab provides a good safety profile of the drug, which is characterized by minimal local and overall adverse effects even during necessary intravitreal application of the treatment.